ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · J Natl Cancer Inst · 2026-11-01

In 278 patients with locally advanced non-nasopharyngeal head and neck squamous cell carcinoma (272 analysed), weekly cisplatin 40 mg/m² with radiation was noninferior to 3-weekly 100 mg/m² for 2-year locoregional control (61.3% vs 51.1%), with fewer grade ≥3 adverse events.

RCTn = 278
Sharma et al. Concurrent chemotherapy and external radiation therapy (ConCERT): phase 3 noninferiority randomized clinical trial of cisplatin weekly vs every 3 weeks in locally advanced squamous cell carcinoma of the head and neck
Ear, nose and throat · Head Neck · 2026-10-05

Meta-analysis of 8 randomised and observational studies (1044 patients) in head and neck SCC: no significant difference between cisplatin- and carboplatin-based regimens in OS, PFS, LRRFS, DMFS or grade ≥3 toxicity; 5-year LRRFS modestly favoured cisplatin (2 studies).

Meta-analysisn = 1,044
Rahim et al. Efficacy and Safety of Cisplatin Versus Carboplatin for Patients With Squamous Cell Carcinoma of Head and Neck: A Systematic Review and Meta-Analysis
Oncology · ESMO Open · 2026-03-19

In a phase 2 trial of 150 patients with untreated metastatic triple-negative breast cancer, gemcitabine plus cisplatin did not significantly improve median PFS vs gemcitabine plus carboplatin (7.8 vs 7.0 months; HR 0.86, P=0.43); median OS was 20.3 vs 19.3 months.

RCTn = 150
Gong et al. A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer
Oncology · ESMO Open · 2026-03-10

Phase 3 RCT in 314 patients with stage IIB–IVA cervical cancer: tri-weekly vs weekly cisplatin chemoradiotherapy did not significantly improve 3-year recurrence-free survival (84.1% vs 78.7%; HR 0.71, P=0.28), but had fewer grade 3–4 haematological toxicities and better QOL.

RCTn = 314 patients
Ryu et al. A randomized phase III clinical trial of weekly versus tri-weekly cisplatin-based chemoradiotherapy for locally advanced cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) study
Gastroenterology · Lancet · 2025-11-20

Phase 3 CASSANDRA trial, first randomisation, 260 patients with resectable or borderline resectable PDAC: preoperative PAXG gave longer median EFS than mFOLFIRINOX (16.0 vs 10.2 months; HR 0.63). Grade ≥3 adverse events: 66% vs 61%.

RCTn = 260
Reni et al. Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.